Perrigo Company plc (PRGO) AI Stock Analysis

Perrigo Company plc provides over-the-counter health and wellness solutions to support self-care. The business operates through two segments: Consumer Self-Care Americas and Consumer Self-Care International. In the Americas, it develops, manufactures, and markets store brand and branded items across categories including upper respiratory, pain relief, digestive health, oral care, and nutrition under brands such as Prevacid 24HR, Good Sense, Plackers, and REACH. Internationally, Perrigo distributes OTC products across approximately 23 countries through pharmacies, wholesalers, and retailers. Additionally, Perrigo provides contract manufacturing services to partners across the healthcare industry.

Perrigo grew revenue from $4.14B in FY2021 to a peak of $4.66B in FY2023, before declining 6.1% to $4.37B in FY2024 and falling 2.8% to $4.25B in FY2025. Gross margin was 35.1% in FY2025, comparable to 34.2% in FY2021, while operating margin reached 8.1%. Net income remained negative across the five-year period, worsening to -$1.43B in FY2025 with a net margin of -33.5%. For the trailing twelve months ended June 30, 2026, revenue stood at $4.14B with a profit margin of -41.9% and an EPS of -$12.28. In the quarter ended June 30, 2026, revenue fell 3.2% year-over-year while quarterly earnings declined 63.6%.

As of June 30, 2026, Perrigo held $399.7M in cash and short-term investments against total debt of $3.29B, resulting in net debt of $2.90B and a debt-to-equity ratio of 1.31. The company maintained liquidity with a current ratio of 2.32 and total assets of $7.61B. In FY2025, operating cash flow reached $238.5M, yielding free cash flow of $145.1M after capital expenditures of $93.4M. Capital deployment during FY2025 included $159.3M in dividends paid, while the 5-year share count increased by 4.5%.

At a market capitalization of $2.30B and enterprise value of $4.82B, Perrigo trades at a forward P/E of 6.0x, below the median of its US-listed Healthcare peers of 17.3x. Its price-to-sales multiple of 0.6x and EV/EBITDA of 8.4x also sit lower than peer medians of 4.1x and 12.0x, respectively. The stock last closed at $16.63 on October 16, 2026, up 27.9% year-to-date and 39.1% above its 200-day average. Over longer periods, PRGO returned -15.5% over 1 year and -53.2% over 5 years, lagging the S&P 500 returns of 16.8% and 83.0%.

Perrigo pays an annual forward dividend of $1.16 per share, representing a dividend yield of 6.98%. The company has paid dividends for 24 consecutive years, delivering a 5-year annualized dividend growth rate of 5.2%. Perrigo distributes its dividend on a quarterly frequency with a reported payout ratio of 46.4%, following an ex-dividend date of August 28, 2026.

Wall Street coverage consists of 1 Strong Buy, 1 Buy, and 3 Hold ratings, with 0 Sell or Strong Sell recommendations. The mean price target of $16.50 implies a -0.8% return relative to the last close of $16.63. Perrigo beat EPS estimates in 3 of the last 4 quarters. For the current fiscal year ending December 31, 2026, consensus estimates project revenue of $4.06B and EPS of $2.19, reflecting an EPS decline of 20.4%. Next fiscal year estimates project revenue of $4.09B and EPS of $2.40 ahead of the next earnings date on November 4, 2026.

This page is an AI-written research summary of Perrigo Company plc (PRGO). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: PRGO income statement, PRGO balance sheet, PRGO key metrics, PRGO analyst forecast, PRGO chart. See the PRGO stock overview for the latest quote and news.